<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03161158</url>
  </required_header>
  <id_info>
    <org_study_id>UF-HF-02-INT</org_study_id>
    <secondary_id>EUDAMED-No. CIV -17-01-018204</secondary_id>
    <nct_id>NCT03161158</nct_id>
  </id_info>
  <brief_title>PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure</brief_title>
  <official_title>PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether tailored, peripheral ultrafiltration complementary to low-dose
      diuretics is associated with a reduction in cardiovascular mortality in 90 days after
      randomization and heart failure events in 90 days after discharge than usual care including
      stepped intravenous diuretics in acutely decompensated chronic heart failure with fluid
      overload (not fully responsive to diuretic therapy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate whether stepped, peripheral ultrafiltration complementary to low-dose
      diuretics influences 90-day clinical outcomes compared to usual care including intravenous
      diuretics in symptomatic heart failure patients with persistent congestion. Hospitalized
      subjects will be randomly assigned to receive either a tailored, peripheral ultrafiltration
      approach complementary to intravenous low-dose diuretics and other guideline-directed medical
      therapy OR high-dose diuretic therapy and other Guideline-directed medical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 3, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, prospective, randomized, parallel-group, controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Failure (HF) Event</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>Heart failure hospitalization or unscheduled outpatient or emergency department treatment with IV loop diuretics or ultrafiltration. All HF Events will be adjudicated by a centralized procedure in which a panel of experts will review and determine cause of event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular death up to 90 days after randomization.</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>The rationale for the follow up time period of 90 days is that death rates reported in previous acute HF trials indicate that mortality seems to become linear after ~60-90 days post discharge Collection for Cardiovascular Trials initiative definition of cardiovascular death includes death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other cardiovascular causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Failure (HF)</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>Analyzing all heart failure hospitalizations gives a more complete picture of treatment benefit in these patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until first heart failure rehospitalization in 90 days after discharge.</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>measured in days failure hospitalization in 90 days after discharge from the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until first unscheduled outpatient or emergency department treatment with IV loop diuretics or ultrafiltration in 90 days after discharge from the index hospitalization.</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (KCCQ-12)</measure>
    <time_frame>in 30 days and 90 days after discharge</time_frame>
    <description>KCCQ-12 (Global Assessment to measure quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5D-5L)</measure>
    <time_frame>in 30 days and 90 days after discharge</time_frame>
    <description>EQ-5D-5L (Global Assessment to measure quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital up to 90 days after discharge.</measure>
    <time_frame>in 90 days after discharge</time_frame>
    <description>at the time of discharge of initial hospitalization, an average of 18 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of congestion every 24 hours during treatment and at discharge.</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>the presence of at least two of the following signs/symptoms (a-c):
Jugular venous pressure of &lt;8cm H2O
Absence of orthopnea (defined as shortness of breath that occurs when lying flat, causing the person to have to sleep propped up in bed or sitting in a chair
Trace peripheral edema or no edema at hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital worsening heart failure until discharge.</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>Physician-determined worsening signs and symptoms of HF and needing addition or initiation of IV or mechanical support during the index hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss at 96 hours after randomization and at discharge.</measure>
    <time_frame>96 hours after randomization and at discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>Decrease in body weight as a measure for reduction of fluid overload</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoint: Bleeding related to venous access</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>Venous access-related complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: infection related to venous access</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>Venous access-related complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety endpoint: thrombosis related to venous access</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>Venous access-related complications</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of stay during initial hospitalization</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>measured in days</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in furosemide-equivalent dose from preadmission to discharge</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>in mg per day</description>
  </other_outcome>
  <other_outcome>
    <measure>all-cause death up to 90 days after randomization</measure>
    <time_frame>through discharge of initial hospitalization, an average of 18 days</time_frame>
    <description>exploratory assessment of all-cause mortality</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">864</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ultrafiltration Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group (Usual care IV diuretics)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Guideline-directed therapy including IV loop diuretics according to treatment algorithm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHIARA-System</intervention_name>
    <description>Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.</description>
    <arm_group_label>Ultrafiltration Group</arm_group_label>
    <other_name>Low-dose IV diuretics</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care IV diuretics</intervention_name>
    <description>Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)</description>
    <arm_group_label>Control group (Usual care IV diuretics)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General:

        Informed consent signed and dated by study patient and investigator/authorised physician

          -  Minimum age of 18 years

          -  Ability to understand the nature and requirements of the study

        Study-specific:

          -  Heart failure patients with preserved, mid-range or reduced ejection fraction
             (confirmed according to the current definitions of heart failure with preserved
             (HFpEF), mid-range (HFmrEF) and reduced ejection fraction (HFrEF) requiring
             echocardiographic assessment within the prior 12 months) who are admitted to the
             hospital due to signs/symptoms of congestion (left- or right sided)

          -  On regularly scheduled oral loop diuretics prior to admission

          -  After pre-screening and prior to final screening for eligibility, patients who have
             received two boluses of IV loop diuretics (Dose according to the Furosemide-Low
             Intensification, Q12 hour bolus arm of the DOSE trial)

          -  Symptoms of congestion and clinical evidence at the time of final screening for
             eligibility:

          -  Fluid overload manifested by at least 2 of the following:

               1. Pitting edema ≥2+ of the lower extremities

               2. Jugular venous pressure &gt;8 cm H2O

               3. Pulmonary congestion or pleural effusion on chest x-ray

               4. Paroxysmal nocturnal dyspnea or ≥2− pillow orthopnea

               5. Respiration rate ≥20 per minute

          -  Additional objective documentation of congestion: Lung or inferior vena cava
             ultrasound, chest x-ray or elevated filling pressures, if available, at the time of
             randomization (optional)

        Exclusion Criteria:

        General:

          -  Any condition which could interfere with the patient's ability to comply with the
             study

          -  In case of female patients, pregnancy or lactation period

          -  Participation in an interventional clinical study during the preceding 30 days

          -  Previous participation in the same study

          -  Unwillingness or inability to complete follow up

          -  Active drug or alcohol abuse (smoking allowed)

        Study-specific:

          -  Acute coronary syndrome requiring intervention during index hospitalization

          -  Severe renal dysfunction requiring renal replacement therapy

          -  Systolic blood pressure &lt; 90 mmHg at the time of randomization

          -  Pulmonary hypertension not secondary to left heart disease

          -  Pulmonary disease thought to be primarily responsible for symptoms

          -  Contraindication to systemic anticoagulation

          -  Severe concomitant disease expected to prolong hospitalization or to cause death in ≤
             90 days

          -  Sepsis

          -  Severe uncorrected valvular stenosis at the time of randomization

          -  Active myocarditis

          -  Hypertrophic obstructive cardiomyopathy

          -  Constrictive pericarditis or restrictive cardiomyopathy

          -  Liver cirrhosis

          -  Known infection with human immunodeficiency virus (HIV) or active hepatitis C

          -  Previous solid organ transplant

          -  Presence or requirement for mechanical respiratory support

          -  Presence or requirement of a mechanical circulatory support device

          -  Need for IV positive inotropic agents at the time of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, Prof Dr med</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsspital Zürich, Klinik für Kardiologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer C. Franke, Dr. med.</last_name>
    <phone>+49 6172 609 7786</phone>
    <email>jennifer.franke@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manuela Stauss-Grabo, Dr.</last_name>
    <phone>+49 6172 609 5248</phone>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen (Med. Klinik II)</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Floege, Prof Dr med</last_name>
      <email>imundt@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nikolaus Marx, Prof Dr med</last_name>
      <email>bcroe@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig, Med. Klinik V</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan T. Kielstein, Prof Dr med</last_name>
      <email>j.kielstein@klinikum-braunschweig.de</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele Eden, Dr. med.</last_name>
      <email>g.eden@klinikum-braunschweig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Lepper, PD Dr med</last_name>
      <email>wolfgang.lepper@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Gabriele Schott, Dr med</last_name>
      <email>gabriele.schott@helios-kliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Paul Hinkel, Dr med</last_name>
      <email>ulrich-paul.hinkel@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Harald Lapp, Prof Dr med</last_name>
      <email>harald.lapp@helios-kliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Innere Medizin III</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Frankenstein, Prof Dr med</last_name>
      <email>lutz.frankenstein@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Hildesheim GmbH</name>
      <address>
        <city>Hildesheim</city>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Kreft, Prof Dr med</last_name>
      <email>burkhard.kreft@helios-kliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>Jürgen Tebbenjohanns, Prof Dr med</last_name>
      <email>juergen.tebbenjohanns@helios-kliniken.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Klinik für Nieren-, Hochdruck- und Autoimmunerkrankungen</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verdat Schwenger, Prof Dr med</last_name>
      <email>v.schwenger@klinikum-stuttgart.de</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Nordt, Prof Dr med</last_name>
      <email>t.nordt@klinikum-stuttgart.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hjärtkliniken Danderyds sjukhus</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Persson, Dr</last_name>
      <email>hans.e.persson@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Helena Rohman, Dr</last_name>
      <email>helena.rohman@sll.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital Huddinge, Department of Cardiology</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars H. Lund, MD AssocProf</last_name>
      <email>lars.lund@alumni.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Petros Athanasopoulos, Dr</last_name>
      <email>petros.athanasopoulos@sll.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital, Department of Cardiology</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ola Vedin, Dr</last_name>
      <email>ola.vedin@ucr.uu.se</email>
    </contact>
    <contact_backup>
      <last_name>Birgitta Jönelid</last_name>
      <email>birgitta.jonelid@medsci.uu.se</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro, Hjärtsviktsmottagningen</name>
      <address>
        <city>Örebro</city>
        <zip>SE-70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barna Szabó, Dr</last_name>
      <email>barna.szabo@regionorebrolan.se</email>
    </contact>
    <contact_backup>
      <last_name>Eszter Marosi</last_name>
      <email>eszter.marosi@regionorebrolan.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2017</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardio-Renal Syndrome type 1</keyword>
  <keyword>Acutely decompensated chronic heart failure</keyword>
  <keyword>Ultrafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

